CompletedEUCTR 2021-003154-23
A Phase II, 8-week-treatment, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, tolerability and safety of orally administered BI 1358894 in ...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesPTSD
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Croatia · Finland and 2 more locations
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 286
- Sponsor
- Boehringer Ingelheim AB
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Croatia, Finland, Poland, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2021-003154-23
- Official title
Show the full official title
A Phase II, 8-week-treatment, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, tolerability and safety of orally administered BI 1358894 in ...
Get this study by email
Recruitment & locations
CompletedCroatia · Finland · Poland
1 more locations
- Sweden
Questions about this study
Who is behind this study?
The study sponsor is Boehringer Ingelheim AB.
